Editas MedicineLTS:0IFK 48 Market Cap is $560.14 Mil as of Jul. 04, 2026. GuruFocus rates LTS:0IFK with a GF Score™ of 48/100 and a GF Value™ of $1.80 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 1,426 Biotechnology companies, Editas Medicine ranks better than 72.72% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Editas Medicine's share price for the quarter that ended in Mar. 2026 was $2.475. Editas Medicine's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 97.90 Mil. Therefore, Editas Medicine's market cap for the quarter that ended in Mar. 2026 was $242.30 Mil.
Editas Medicine's quarterly market cap
declined
from Sep. 2025 ($315.23 Mil) to Dec. 2025 ($201.61 Mil) but then
increased
from Dec. 2025 ($201.61 Mil) to Mar. 2026 ($242.30 Mil).
Editas Medicine's annual market cap
declined
from Dec. 2023 ($832.39 Mil) to Dec. 2024 ($102.56 Mil) but then
increased
from Dec. 2024 ($102.56 Mil) to Dec. 2025 ($201.61 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Editas Medicine's Enterprise Value for Today is $453.79 Mil.
Editas Medicine (LTS:0IFK) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Editas Medicine Market Cap Related Terms
Editas Medicine Market Cap Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IFK vs SGMT, AUTL, FBRX: Market Cap Comparison
For the Biotechnology subindustry, Editas Medicine's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Market Cap distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Editas Medicine's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (LTS:0IFK) has a Market Cap of $560.14 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #389 out of 1426 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Editas Medicine's Market Cap too high?
Editas Medicine's current Market Cap is $560.14 Mil. The Biotechnology industry median Market Cap is 119.23. Editas Medicine's value of $560.14 Mil is 369.8% above this industry median. Based on the distribution chart, Editas Medicine ranks #389 out of 1426 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Editas Medicine has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Market Cap compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #389 out of 1426 companies for Market Cap. This puts Editas Medicine in the upper half of its industry. The industry median Market Cap is 119.23. Editas Medicine's value of $560.14 Mil is 369.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current Market Cap of $560.14 Mil is 369.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Market Cap is $560.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (LTS:0IFK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.80, compared to a current price of $3.50 — trading 94.4% above its estimated fair value. The current Market Cap is $560.14 Mil and 369.8% above the Biotechnology industry median of 119.23. Editas Medicine's overall GF Score™ is 48/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Editas Medicine (LTS:0IFK), the current Market Cap is $560.14 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (LTS:0IFK) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.50 is trading 94.4% above its estimated GF Value™ of $1.80.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for LTS:0IFK:
Market Cap: $560.14 Mil
GF Value™: $1.80 vs. price of $3.50 (94.4% above fair value)
Industry Position: 369.8% above the Biotechnology median (#389 of 1426)
No single metric tells the full story. See the LTS:0IFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
48GF Score
Get the complete analysis for LTS:0IFK
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IFK has been successfully added to your 
